Filed in archive
Corporate and Industrial News
, Drugs, Vaccines and Therapeutics
by ruth on January 25, 2007
MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development both for the treatment of insomnia as well as for anxiety disorders such as generalized anxiety disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of mutagenicity, antigenicity or carcinogenicity. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects.
MediciNova acquired a license to MN-305 from Mitsubishi Pharma Corporation for global markets, with the exception of Japan and other selected Asian countries.
Source: MediciNova
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/50678
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for MediciNova Initiates Phase II Trial on Insomnia Pill:
|
Rating: 10.00 out of 1 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
